Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulvestrant plus ribociclib vs physician’s choice in HR+, HER2- metastatic breast cancer after adjuvant CDK4/6 inhibitors (CLEE011AKR06R)
KCT0010630Phase 2Not yet recruiting
- Sponsor
- Novartis
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of ribociclib and fulvestrant in breast cancer (2 arms), sponsored by Novartis. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
ribociclibfulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on KCT0010630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0010630.